Literature DB >> 5009114

Long-term kinetics of serum and xanthoma cholesterol radioactivity in patients with hypercholesterolemia.

P Samuel, W Perl, C M Holtzman, N D Rochman, S Lieberman.   

Abstract

In four patients with hypercholesterolemia (type II hyperlipoproteinemia) and xanthomatosis the decay of serum cholesterol specific activity was followed for 53-63 wk after pulse labeling. Specific activity of biopsied xanthoma cholesterol was measured four times in the course of the study. The xanthoma specific activity curve crossed and thereafter remained above the serum specific activity curve. The average ratio of xanthoma to serum specific activity was 4.7 at the end of the study. The final half-time of the xanthoma decay curves was significantly greater (average: 200 days) than the slowest half-time of serum specific activity decay (average: 93 days). The data were analyzed by input-output analysis and yielded the following results. The average value for the total input rate of body cholesterol (I(T)) (sum of dietary and biosynthesized cholesterol) was 1.29 g/day. The average size of the rapidly miscible pool of cholesterol (M(a)) was 55.7 g. and of the total exchangeable body mass of cholesterol (M) 116.5 g. The average value of M - M(a) (remaining exchangeable mass of cholesterol) was 60.8 g. The derived values for exchangeable masses of cholesterol, in the present patients with marked hypercholesterolemia, were significantly larger than in a group of patients with normal serum lipids in previous studies. One of the four patients died of a sudden acute myocardial infarction 53 wk after pulse labeling. Specific activity of aortic wall and atheroma cholesterol was 3.12 times that of serum. The ratio was close to 2 for adipose tissue and spleen, and was slightly above 1 or was close to unity in most other organs studied, with the exception of brain which showed a ratio of 0.19.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 5009114      PMCID: PMC302124          DOI: 10.1172/JCI106811

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Input-output analysis for total input rate and total traced mass of body cholesterol in man.

Authors:  W Perl; P Samuel
Journal:  Circ Res       Date:  1969-08       Impact factor: 17.367

2.  The metabolism of cholesterol in two hypercholesterolaemic patients treated with cholestyramine.

Authors:  C D Moutafis; N B Myant
Journal:  Clin Sci       Date:  1969-10       Impact factor: 6.124

3.  Indicator equivalence theorem for input rates and regional masses in multi-inlet steady-state systems with partially labeled input.

Authors:  W Perl; R M Effros; F P Chinard
Journal:  J Theor Biol       Date:  1969-11       Impact factor: 2.691

4.  Long-term decay of serum cholesterol radioactivity: body cholesterol metabolism in normals and in patients with hyperlipoproteinemia and atherosclerosis.

Authors:  P Samuel; W Perl
Journal:  J Clin Invest       Date:  1970-02       Impact factor: 14.808

5.  Distribution and turnover of cholesterol in humans.

Authors:  P J Nestel; H M Whyte; D S Goodman
Journal:  J Clin Invest       Date:  1969-06       Impact factor: 14.808

6.  Tracer dynamics and the determination of pool-sizes and turnover factors in metabolic systems.

Authors:  P E Bergner
Journal:  J Theor Biol       Date:  1964-03       Impact factor: 2.691

7.  Effect of neomycin on exchangeable pools of cholesterol in the steady state.

Authors:  P Samuel; C H Holtzman; E Meilman; W Perl
Journal:  J Clin Invest       Date:  1968-08       Impact factor: 14.808

8.  Measurements of cholesterol turnover, synthesis, and absorption in man, carried out by isotope kinetic and sterol balance methods.

Authors:  S M Grundy; E H Ahrens
Journal:  J Lipid Res       Date:  1969-01       Impact factor: 5.922

9.  The measurement of the exchangeable pools of cholesterol in the baboon.

Authors:  J D Wilson
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

10.  Turnover of plasma cholesterol in man.

Authors:  D S Goodman; R P Noble
Journal:  J Clin Invest       Date:  1968-02       Impact factor: 14.808

View more
  9 in total

Review 1.  [Cell receptor defects as the cause of endocrine and metabolic diseases (author's transl)].

Authors:  W Gerok
Journal:  Klin Wochenschr       Date:  1979-06-15

2.  Cholesterol metabolism in the diabetic Chinese hamster.

Authors:  A V Chobanian; G C Gerritsen; P I Brecher; M Kessler
Journal:  Diabetologia       Date:  1974-11       Impact factor: 10.122

3.  Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.

Authors:  S M Grundy; D W Bilheimer
Journal:  Proc Natl Acad Sci U S A       Date:  1984-04       Impact factor: 11.205

4.  Treatment of familial hypercholesterolemia by portacaval anastomosis: effect on cholesterol metabolism and pool sizes.

Authors:  D J McNamara; E H Ahrens; R Kolb; C D Brown; T S Parker; N O Davidson; P Samuel; R M McVie
Journal:  Proc Natl Acad Sci U S A       Date:  1983-01       Impact factor: 11.205

5.  Cholesterol metabolism in human obesity.

Authors:  P J Nestel; P H Schreibman; E H Ahrens
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

6.  The metabolism of cholestanol, cholesterol, and bile acids in cerebrotendinous xanthomatosis.

Authors:  G Salen; S M Grundy
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

7.  The turnover of cholesterol in human atherosclerotic arteries.

Authors:  S N Jagannathan; W E Connor; W H Baker; A K Bhattacharyya
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

8.  Interaction of collagen with the lipids of tendon xanthomata.

Authors:  A R Tall; D M Small; R S Lees
Journal:  J Clin Invest       Date:  1978-10       Impact factor: 14.808

Review 9.  The role of the lymphatic system in cholesterol transport.

Authors:  Li-Hao Huang; Andrew Elvington; Gwendalyn J Randolph
Journal:  Front Pharmacol       Date:  2015-09-02       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.